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Objective: To assess currently available evidence on adrenal incidentaloma and provide recommen-
dations for clinical practice.
Design: A panel of experts (appointed by the Italian Association of Clinical Endocrinologists (AME))
appraised the methodological quality of the relevant studies, summarized their results, and discussed
the evidence reports to find consensus.
Radiological assessment: Unenhanced computed tomography (CT) is recommended as the initial test
with the use of an attenuation value of%10 Hounsfield units (HU) to differentiate between adenomas
and non-adenomas. For tumors with a higher baseline attenuation value, we suggest considering
delayed contrast-enhanced CT studies. Positron emission tomography (PET) or PET/CT should be
considered when CT is inconclusive, whereas fine needle aspiration biopsy may be used only in selected
cases suspicious of metastases (after biochemical exclusion of pheochromocytoma).
Hormonal assessment: Pheochromocytoma and excessive overt cortisol should be ruled out in all
patients, whereas primary aldosteronism has to be considered in hypertensive and/or hypokalemic
patients. The 1 mg overnight dexamethasone suppression test is the test recommended for screening of
subclinical Cushing’s syndrome (SCS) with a threshold at 138 nmol/l for considering this condition. A
value of 50 nmol/l virtually excludes SCS with an area of uncertainty between 50 and 138 nmol/l.
Management: Surgery is recommended for masses with suspicious radiological aspects and masses
causing overt catecholamine or steroid excess. Data are insufficient to make firm recommendations for
or against surgery in patients with SCS. However, adrenalectomy may be considered when an adequate
medical therapy does not reach the treatment goals of associated diseases potentially linked to
hypercortisolism.
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Adrenal masses are among the most prevalent human
tumors and are frequently detected unexpectedly by an
imaging study performed for reasons unrelated to
suspect of adrenal diseases. The widespread use of
computed tomography (CT), diagnostic ultrasound,
and magnetic resonance imaging (MRI) has resulted in
the frequent incidental discovery of asymptomatic
adrenal masses. Such masses are commonly defined as
adrenal incidentalomas and represent a public health
challenge because they are increasingly recognized in
current medical practice (1). Adrenal incidentalomas
raise challenging questions for both physicians and their
patients and represent one of the leading reasons forndocrinologyseeking endocrinological consultation. On the basis of
these considerations, the Italian Association of Clinical
Endocrinologists (AME) considered it timely and appro-
priate to appoint a panel of Italian experts in the field of
adrenal diseases with the task to write a Position
Statement whose intent was to assess and synthesize
currently available data regarding adrenal incidenta-
loma and provide recommendations for clinical practice.Methodology
Adrenal incidentaloma is not a single entity, rather it
is an ‘umbrella’ definition comprising a spectrum of
different pathological entities that share the same pathDOI: 10.1530/EJE-10-1147
Online version via www.eje-online.org
852 M Terzolo and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 164of discovery. The likelihood of any specific condition
greatly depends on the definition of incidentaloma and
the circumstances of discovery. Unfortunately, published
reports are inconsistent in applying definite inclusion
and exclusion criteria, making their results difficult to
interpret. Including patients with signs and symptoms
attributable to an adrenal tumor will increase the
proportion of large masses or biochemically active
tumors. Conversely, studies that exclude patients with
signs or symptoms will find a greater proportion of small
masses and biochemically silent tumors. As the
definition of incidentaloma was heterogeneous across
the studies, the panel accepted all studies independent of
their respective definitions of incidentaloma, rather
than choosing a narrow definition that may exclude
potentially relevant studies.
The panel searched for and summarized evidence on
several key questions on adrenal incidentalomas that
were formulated by the panel prior to evaluating the
literature with the aim to provide recommendations for
clinical practice (Table 1). A comprehensive search of
the medical literature was then conducted to identify
relevant studies that were identified primarily through a
MEDLINE search of the English language literature
published between 1966 and 2009. References of
selected review articles were also examined to identify
additional studies and other reports that were
considered relevant by the panel. The panel appraised
the methodological quality of the studies that met the
inclusion criteria, summarized their results, and
discussed the evidence reports to find consensus. The
Position Statement was reviewed by a group of
distinguished international experts and the panel
incorporated changes needed in response to their
written comments.
The methodology of the present Position Statement is
based on the grading of recommendations, assessment,
development and evaluation (GRADE) system (GRADE
Working Group website. http://www.gradeworking-
group.org) (2, 3). The GRADE system requires that
the quality of evidence is integrated with other factors,Table 1 Key questions on adrenal incidentalomas addressed by
the panel.
1. What is the frequency of an incidental adrenal mass in the
population?
2. What are the causes of an incidental adrenal mass in the
population?
3. What is the diagnostic accuracy of the imaging modalities used to
differentiate the various types of adrenal incidentalomas?
4. What is the diagnostic accuracy of the various biochemical tests
used to detect secretory activity of adrenal incidentalomas?
5. What is the risk of malignant transformation of an adrenal
incidentaloma?
6. What is the risk of evolution toward overt hypersecretion?
7. What is the morbidity and mortality of subclinical Cushing’s
syndrome?
8. What is the management for subclinical Cushing’s syndrome?
9. What is the surgical technique for adrenalectomy?
10. How to perform follow-up?
www.eje-online.orgso that the strength of recommendations is not
necessarily, although in most cases is, related to the
levels of evidence. The panel used ‘recommend’ for
strong recommendations and ‘suggest’ for weak
recommendations.Epidemiology
Questions
1. What is the frequency of an incidental adrenal
mass in the population? Available information is
scarce and extrapolated from either clinical or autopsy
studies. Most experts agree on considering adrenal
masses of 10 mm, or more, in size as incidentalomas,
although different criteria were used to define a discrete
adrenal mass (4–7). In autopsy studies, the mean
prevalence of clinically inapparent adrenal masses
is about 2.0%, ranging from 1.0 to 8.7% (4–6).
Prevalence increases with age with no difference in sex
(4–9) and is higher in white than in black people (3, 9)
and also in obese, diabetic, and hypertensive patients (6).
In clinical studies, prevalence figures have most likely
underestimated the actual frequency of adrenal inci-
dentalomas because most data were generated with
radiological equipment now considered obsolete, as
imaging technology has considerably improved in
recent years. In radiological studies, the frequency of
adrenal incidentalomas was estimated at w4% in
middle age and increases up to more than 10% in the
elderly, peaking around the fifth and seventh decade
(6–10). Adrenal incidentalomas are slightly more
frequent in women as a result of a referral bias (8, 9).
The frequency of adrenal incidentalomas is very low in
childhood and adolescence accounting for 0.3–0.4% of
all tumors in children (11).
2. What are the causes of an incidental adrenal
mass in the population? Etiology includes either
benign or malignant lesions. There is consistent
evidence that most adrenal incidentalomas are benign
adrenal adenomas that account for w80% of all
tumors, even if a precise estimate is impossible because
adrenal adenomas are rarely excised (4–10, 12–14).
The frequency of pheochromocytoma ranges between
1.5 and 23%, whereas adrenocortical cancer (ACC)
varies from 1.2 to 12% (4–6, 8, 14) among different
studies. Such a great variability in the reported
frequency of pheochromocytoma, ACC, and other
histological diagnoses depends on the inclusion criteria
and referral pattern of the various studies. Accordingly,
the most frequent tumor types as they are reported in
clinical and surgical studies are reported in Table 2.
A recent review of the literature concluded that the
prevalence of malignant and functional lesions is likely
to have been overestimated in the literature (15). The
figures reported in most papers are likely to be biased by
Table 2 Frequency of the different types of adrenal incidentaloma.
Type Average (%) Range
Clinical studies*
Adenoma 80 33–96
Non-functioning 75 71–84
Cortisol secreting 12 1.0–29
Aldosterone secreting 2.5 1.6–3.3
Pheochromocytoma 7.0 1.5–14
Carcinoma 8.0 1.2–11
Metastasis 5.0 0–18
Surgical studies**
Adenoma 55 49–69
Non-functioning 69 52–75
Cortisol secreting 10 1.0–15
Aldosterone secreting 6.0 2.0–7.0
Pheochromocytoma 10 11–23
Carcinoma 11 1.2–12
Myelolipoma 8.0 7.0–15
Cyst 5.0 4.0–22
Ganglioneuroma 4.0 0–8.0
Metastasis 7.0 0–21
*Data from references (6, 8, 9). **Data from references (4, 6, 8, 9, 14–17).
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with a history of malignancy. In their review, Cawood
et al. (15) estimated a frequency around 2.0% for ACC,
!1.0% for adrenal metastases and around 3.0% for
pheochromocytoma. These figures are lower than those
generally reported in reviews that did not use a narrow
definition of adrenal incidentaloma but accepted all
studies with their own definition. In such highly
referenced reviews, prevalence of ACC was reported in
the range of 4.0–5.0%, pheochromocytoma 5.0–6.0%,
and metastasis 2.0% (4, 9, 16). Cysts, ganglioneur-
omas, myelolipomas, hematomas, and metastases from
extra-adrenal cancers represent other possible causes of
adrenal incidentalomas (4, 6, 8, 17). The adrenal
glands are frequently affected by metastatic spreading of
a variety of primary cancers (lung cancer, breast cancer,
kidney cancer, melanoma, and lymphoma) and in
cohorts of oncological patients, 50–75% of adrenal
incidentalomas are metastases (7, 18–20). An adrenal
incidentaloma may represent a metastasis from an
unknown extra-adrenal malignancy; this presentation
of an advanced malignancy is unusual and was found to
occur in 5.8% of over 1600 patients with various types
of carcinoma when both the adrenal glands were
affected, but only in 0.2% when adrenal involvementTable 3 Clinical recommendations based on epidemiology of adrena
1. We recommend considering the possibility of primary adrenal malign
adrenal incidentalomas. 1444B
2. We recommend excluding adrenal metastases in oncological patie
3. We recommend excluding primary adrenal malignancies in all pedi
The panel used the GRADE system to classify evidence in four quality levels that
evidence;44BB, low quality;444B, moderate quality; and4444, high
recommendations (term used: ‘we recommend’ and the number 1) and low- o
‘we suggest’ and the number 2), this link is not mandatory.was monolateral (21). However, ACC represents 1.3% of
all malignancies in patients !20 years and ACC
frequency peaks at !4 years (22).
Up to 15% of patients with adrenal incidentaloma
have bilateral adrenal masses, and the most likely
diagnoses are metastatic or infiltrative diseases of the
adrenal glands, congenital adrenal hyperplasia,
bilateral cortical adenomas, and ACTH-independent
macronodular adrenal hyperplasia (AIMAH) (23).
The prevalence results derived by combining data
from the reported study should be interpreted with
caution. The lack of a uniform definition of incidenta-
loma (and the consequent heterogeneity of inclusion
and exclusion criteria), the selective sampling of
patients and reporting of information, and the retro-
spective nature of most of the studies may result in
biased estimations of the prevalence of various path-
ologies. The underlying distribution of adrenal path-
ology in incidentaloma is influenced by a number of
factors that were not consistently controlled in many of
the studies. The limitations of epidemiological data due
to inherent bias of the literature, and the paucity of
studies done in the general healthy population, allow a
few recommendations for clinical practice. Recommen-
dations for clinical practice based on epidemiology of
adrenal incidentalomas are given in Table 3.Radiological assessment
Questions
1. What is the diagnostic accuracy of the imaging
modalities used to differentiate the various types of
adrenal incidentalomas? A common limitation of the
available studies is the use of broad inclusion criteria,
which included not only adrenal incidentalomas
but also clinically overt adrenal masses. Moreover,
ascertainment of outcome with a definitive pathological
diagnosis was missing in most cases. With few
exceptions (24), the final diagnosis was most frequently
inferred from stability of the adrenal mass over variable
periods of observation (at least 6 months). Another
common limitation is the lack of a clear definition of the
test accuracy that, therefore, had to be indirectly
inferred. In general, sensitivity refers to the percentage
of subjects with an adrenal malignancy (either ACC or
metastasis) with a positive test, and specificity refers tol incidentalomas.
ancies and metastases from extra-adrenal tumors in all patients with
nts with adrenal incidentalomas. 14BBB
atric patients with adrenal incidentalomas. 14444
are shown by cross-filled circles, such that4BBB denotes very low-quality
quality. Although usually high- or moderate-quality evidences generate strong
r very low-quality evidences generate weak recommendations (term used:
www.eje-online.org
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nancy with a negative test. However, a clear differen-
tiation between ACC and metastases has inconsistently
been pursued. Pertinently, relatively few patients with
ACC compared with adrenal metastases have been
included in the radiological studies that are mostly
retrospective.
Ultrasonography. The use of ultrasonography (US)
depends on a large extent on operator skill. Obesity
and overlying gas are frequent obstacles for visual-
ization of the adrenal glands (25). Thus, US does not
detect adrenal masses with the same sensitivity as CT or
MRI (26, 27). According to one study (28), the
sensitivity in detecting incidentalomas depends on the
mass size, being 65% for lesions !3 cm and 100% for
lesionsO3 cm. Another study found that US has a good
reliability in evaluating mass size and its growth with
time but has no role in differentiating between benign
and malignant adrenal masses (29).
Unenhanced CT. A key point is that most abdominal and
chest CT scans leading to the unexpected discovery of an
adrenal mass are obtained with the use of i.v. contrast
and may not fulfill current technical recommendations
for an optimal CT study of the adrenal glands, including
analysis on contiguous 3–5 mm-thick CT slices, pre-
ferentially on multiple sections using multidetector row
protocols (30). In those cases, it may be worthwhile to
obtain an unenhanced CT scan specifically aimed for the
study of the adrenal glands (13).
Both CT and MR are lipid-sensitive imaging tests that
exploit the fact that up to 70% of adrenal adenomas
contain abundant intracellular fat, whereas almost all
malignant lesions do not (4–6). There is an inverse
linear relationship between fat concentration and
attenuation on unenhanced CT images. Thus, the CT
densitometry technique shows that the mean attenu-
ation value of adenomas is significantly lower than that
of the non-adenomas. CT densitometry is key because
the structural features of most adrenal masses are not
specific to allow a precise characterization. The size and
appearance of an adrenal mass on CT may help to
distinguish between benign and malignant lesions. In
previous studies, a cutoff of 4 cm in size has been
reported to be the most reliable way to diagnose
malignancy (or non-adenomatous lesions) but with a
very low specificity (4, 8, 16). More recent studies found
that CT attenuation value, expressed in Hounsfield units
(HU), is a superior parameter but can also be used
in composite criteria (24). A total of six studies (730
patients) showed that a density of%10 HU had the best
accuracy with a sensitivity of 96–100% and a specificity
of 50–100% in differentiating benign to malignant
masses (24, 31–35). Lesions with a densityO10 HU on
unenhanced CT are considered indeterminate and other
tests are generally required for characterization,
because 30% of adrenal adenomas are lipid-poor
tumors that may show attenuation values O10 HUwww.eje-online.org(31–35). A single study suggested that all non-calcified,
non-hemorrhagic adrenal lesions with attenuation
values of O43 HU should be considered suspicious for
malignancy (30).
Enhanced CT. The percentage washout on delayed
images contributes to the differentiation between
adenomas and malignant adrenal masses because
enhancement – i.e. ‘washout’– decreases more quickly
in adenomas than malignant masses: a 10–15 min
delay after administration of contrast medium was
accepted by most authors (30–35). There are two
methods to measure percentage washout: absolute
percentage washout (APW) and relative percentage
washout (RPW). Blake et al. (30) provided the following
formulas:
APWZ100!ðEAKDAÞ=ðEAKPAÞ
RPWZ100!ðEAKDAÞ=EA
where EA is attenuation on contrast-enhanced scans
(60–70 s after administration of contrast medium), DA
is attenuation on delayed contrast-enhanced scans
(protocol with 10 min delay), and PA is pre-contrast
attenuation. All attenuation measurements are in HU.
Lipid-poor adenomas represent 10–40% of adenomas
and typically demonstrate rapid washout with an
absolute washout of more than 60% (sensitivity of
86–100%, specificity of 83–92%) and a relative
washout of more than 40% (sensitivity of 82–97%,
specificity of 92–100%) on delayed images (34). After
contrast medium administration, metastases usually
demonstrate slower washout on delayed images
(APW!60%, RPW!40%) than adenomas. ACC typi-
cally has a RPW of !40%; however, large size and
heterogeneity are more reliable indicators of malig-
nancy than washout values (36). ROC analysis of the
performance of APW and RPW criteria in enabling
differentiation between benign and malignant adrenal
masses (excluding pheochromocytomas, cysts, and
myelolipomas from analysis) showed that APW criteria
were more discriminating than RPW criteria (30). The
APW allows a more accurate calculation of the mass
enhancement, because the pre-contrast attenuation
value is included in the formula, thus resulting in a
more accurate characterization of the washout.
However, all the studies had limitations due to the
retrospective analysis of data and the fact that the
nature of most adrenals masses was not pathologically
proved but was often assumed by imaging follow-up, so
that stable dimensions over a given period were
considered as demonstrating a benign nature (34). In
one study, enhanced CT was done as a second-line
procedure when mass density was O10 HU on
unenhanced CT and that enabled a better differentiation
of adenomas from non-adenomas (33). Delayed con-
trast-enhanced CT is emerging as an extremely accurate
imaging test to differentiate adrenal lesions, although
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threshold allowing the most accurate differentiation of
adenomas from non-adenomas. Furthermore, there is
some heterogeneity in the data on sensitivity and
specificity of this technique across different studies.
Magnetic resonance imaging. MRI is as effective as CT in
distinguishing benign from malignant lesions. The
differentiation between benign and malignant masses
was based more on the findings from chemical shift
studies than on the signal intensities of conventional
techniques. Chemical shift imaging relies on the
different resonance frequencies of protons in water
and triglyceride molecules and, therefore, may permit a
more specific diagnosis of adrenal adenomas, known to
contain abundant lipids. The studies reported quan-
titative or qualitative analysis of signal intensity loss in
the adrenal lesions relative to reference tissues (liver,
muscle, and spleen) on in-phase and opposed-phase
sequences as means to differentiate adenomas from
non-adenomas. The loss of signal on out-of-phase
images in relation to spleen (to avoid the confounding
of liver steatosis) differentiated adenomas from non-
adenomas with a sensitivity of 84–100% and a
specificity of 92–100% (37–40). In general, adenomas
appear as hypo- or iso-intense in comparison with the
liver on T1-weighted images and hyper- or iso-intense to
the liver on T2-weighted images. A study proposed the
criterion of hyperintensity on T2-weighted images
(without setting a threshold) to differentiate benign
from malignant masses (41).
Considering that chemical shift MR and unenhanced
CT densitometry tests are both based on the detection of
intracellular lipid, there has been a debate as to which
test might be superior. Studies have shown that for lipid-
rich adenomas, there is no apparent difference between
the tests, but chemical shift imaging might be superior
when evaluating lipid-poor adenomas with an attenu-
ation value up to 30 HU (42, 43). We do not have
enough evidence on the comparison between CT and
MR; however, in the everyday practice, CT plays a
primary role for the radiological assessment of adrenal
incidentalomas. Thus, other imaging tests (including
MR and PET) should only be employed in unusual
circumstances (44–47).
Scintigraphy. In previous studies, two radiocholesterol
derivatives have mainly been studied: 131I-6-b-iodo-
methyl-norcholesterol (NP-59) and 75Se-selenomethyl-
19-norcholesterol for morphological and functional
imaging of adrenal cortex (48). A disadvantage with
the radiotracers is their inherent high radiation dose
(49). A concordant scintigraphic pattern, defined as a
unilateral adrenal visualization, or increased radio-
tracer uptake at the side of the detected mass, has been
proposed as a typical pattern of benign cortical
adenoma or nodular hyperplasia. In contrast, a
discordant pattern with absent, decreased, or distorted
uptake by the adrenal mass may indicate ACC,metastasis, or other nonfunctioning, space-occupying,
or destructive adrenal lesions; two studies found that
sensitivity ranged from 71 to 100% and specificity
ranged from 50 to 100% for differentiating benign
from malignant lesions (50, 51). Owing to the limited
resolution of scintigraphy, concordant and discordant
patterns of uptake may not be demonstrable in lesions
!2.0 cm in diameter (51, 52). Also it has to be
considered that some benign adrenal tumors of extra-
cortical origin, i.e. myelolipoma, do produce a
discordant pattern of uptake (suggestive of a malig-
nancy) and well-differentiated ACC may show uptake
of the tracer. These exceptional ACCs are usually
associated with overt Cushing’s syndrome or miner-
alocorticoid excess (53).
NP-59 adrenal scintigraphy was also extensively used
to assess functional autonomy of adrenal incidentalo-
mas (adenomas) and to differentiate functioning from
non-functioning tumors (9, 50, 53). Some adrenal
adenomas can produce an amount of cortisol sufficient
to reduce ACTH secretion and suppress the uptake of the
contralateral gland as well, but not enough to cause
clinically overt signs, in analogy with hot, pre-toxic,
thyroid nodules (4–6, 9, 51). NP-59 uptake on the side
of the mass with non-visualization of the contra-lateral
adrenal gland (concordant uptake) may occur despite
overall normal endocrine tests (12). Scintigraphic
uptake thus represents a very precocious sign of
functional autonomy, but the low specificity of this
finding makes it of a doubtful clinical utility.
Overall, insufficient spatial resolution, lack of wide-
spread expertise, limited availability of the tracer, and
length of the procedure, which requires serial scanning
over a 5- to 7-day span, are the main inconveniences of
adrenal scintigraphy (52).
PET scan. The concept of 18F-FDG PET is based on an
increased glucose uptake by malignant lesions. The
quantitative analysis of FDG uptake is performed using
standardized uptake values (SUV) or by qualitative
visual evaluation with respect to liver uptake. The
sensitivity of FDG-PET in identifying malignant lesions
varied between 93 and 100% with a specificity between
80 and 100% (54–58). Necrotic or hemorrhagic
malignant adrenal lesions may cause false-negative
results showing poor FDG uptake. PET imaging is not
reliable for lesions !1 cm in size, as metastatic lesions
of this size may demonstrate less radiotracer uptake
than normal liver.
Recent studies demonstrated that a maximal SUV
ratio (adrenal to liver maximal SUV activity) !1.45–
1.60 is highly predictive of a benign lesion (59–63). The
use of PET/CT may offer advantages over PET alone as
the morphology of the lesion can be assessed by CT,
although its metabolic activity is measured concomi-
tantly by PET, allowing for accurate anatomic local-
ization of any FDG focal uptake. CT densitometry and
washout measurements (if a delayed contrast-enhancedwww.eje-online.org
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The sensitivity of PET-CT ranged between 98.5 and
100% and specificity ranged between 92 and 93.8%
(60–63). The addition of washout measurements on
contrast-enhanced CT in one study increased specificity
to 100% (64).
18F-FDG PET or PET/CT may be a useful tool for
distinguishing potentially malignant lesions from
benign tumors in radiologically indeterminate adrenal
lesions; thus, patients who have an adrenal lesion with
inconclusive CT densitometry or washout analysis
should be referred for characterization with 18F-FDG
PET (44, 59). Sensitivity of 18F-FDG PET imaging is only
moderate, however, for the diagnosis of small lesions
and also false-positive results have to be considered (i.e.
some adrenal adenomas and pheochromocytomas may
uptake FDG). Because of its excellent negative predictive
value, 18F-FDG-PET may help in avoiding unnecessary
surgery in patients with non-secreting equivocal tumors
at CT scanning and low 18F-FGD uptake. Moreover,
18F-FDG PET may favor surgical removal of tumors with
elevated uptake and no biochemical evidence of
pheochromocytoma (60).
For differentiation between lesions of adrenocor-
tical and non-adrenocortical origin metomidate,
11C-metomidate PET has been introduced as a PET
tracer (65, 66) as it specifically binds to adrenal
CYP11B enzymes. Translation into clinical practice of
11C-metomidate PET is hampered by the need of on-site
cyclotrons, justifying introduction of the SPECT tracer
123I-iodometomidate. Preliminary data show that this
new tracer specifically accumulates in adrenocortical
tissue with excellent visualization of benign adrenal
tumors; however, tracer uptake in patients with ACC is
heterogeneous and may be affected by treatment (67).
Metomidate-based tracers hold promise to refine our
ability to characterize functionally adrenal tumors but
are not yet widely available.
Fine needle aspiration biopsy. Studies reported a sensitivity
of 81–96% and a specificity of 99–100% to identify
malignant masses. Inconclusive biopsies were reported
in 6–50% of samples (68–70). Complications of fineTable 4 Clinical recommendations on the radiological assessment of
1. We recommend unenhanced CT as the initial imaging procedure. W
leading to the discovery of an adrenal mass was of suboptimal tech
2. We recommend against diagnostic US as a routine imaging techni
3. We recommend against adrenal scintigraphy as a routine imaging
4. We recommend the use of an attenuation value of%10 HU on une
5. For tumors with a higher baseline attenuation value, we suggest co
6. We recommend against FDG-PET as a routine imaging technique
7. We suggest considering PET or PET/CT when CT densitometry or
244BB
8. We recommend against FNAB as a routine diagnostic technique. It m
for metastases of extra-adrenal cancer and inconclusive results of
244BB
For terminology of the strength of recommendations and graphical description
www.eje-online.orgneedle aspiration biopsy (FNAB) have not been
adequately reported in all studies; however, the rate of
adverse events is ranging from 2.8 to 14%. No reliable
estimates can be made about the relative safety of the
different biopsy techniques; however, performing FNAB
carries a small but definitive risk of morbidity and
mortality from pneumothorax, bleeding, infection, and
pancreatitis (6, 71). Moreover, biopsy of an ACC may
result in needle track seeding of tumor cells (16, 72).
The necessity for FNAB has been reduced by the
accuracy of contemporary adrenal imaging techniques
designed to characterize adrenal disease (72, 73).
FNAB is not accurate in differentiating benign from
malignant primary adrenal tumors and may be useful
in selected cases only, in patients with a history of an
underlying extra-adrenal malignancy and inconclusive
results of imaging tests, or if there is suspicion of a rare
tumor (47, 73). It is mandatory to biochemically
exclude a pheochromocytoma before FNAB is performed
(74). Recommendations on the radiological assessment
of adrenal incidentalomas are given in Table 4.Hormonal evaluation
All subjects with an incidentally discovered adrenal
mass should be screened for both catecholamine
overproduction and hypercortisolism, with the excep-
tion of patients with adrenal masses whose imaging
characteristics are typical for myelolipoma or adrenal
cyst. Primary hyperaldosteronism should be considered
in hypertensive and/or hypokalemic patients. Using the
strictest inclusion criteria and the purest definition of
incidentaloma, which imply the lack of the more specific
signs of hypercortisolism, will reduce the proportion of
secretory tumors and will virtually eliminate the
possibility of overt Cushing’s syndrome (5, 13, 16).
However, physicians who are not familiar with
Cushing’s syndrome might overlook (mild) signs of
hypercortisolism and will pursue evaluation of adrenal
function only following the (incidental) discovery of an
adrenal mass.adrenal incidentalomas.
e recommend to repeat unenhanced CT whenever the baseline scan
nique. 144BB
que to characterize an adrenal incidentaloma. 144BB
technique to characterize an adrenal incidentaloma. 144BB
nhanced CT to diagnose an adrenal adenoma. 1444B
nsidering delayed contrast-enhanced CT studies. 244BB
to characterize adrenal incidentalomas. 144BB
washout analysis is inconclusive or suspicious for malignancy.
ay be used only in selected patients with adrenal masses suspicious
imaging tests (after biochemical exclusion of pheochromocytoma).
of quality of evidence, see the legend of Table 1.
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1. What is the diagnostic accuracy of the various
biochemical tests used to detect secretory activity of
adrenal incidentalomas?
Screening of pheochromocytoma. Screening for pheochro-
mocytoma should also be done in normotensive patients
even if the imaging characteristics of the tumor are not
suggestive for a catecholamine-producing tumor (5, 13,
16). In all patients with adrenal incidentalomas,
fractionated metanephrines should be measured in
urine (sensitivity 97%) or free metanephrines in plasma
(sensitivity 99%) (75, 76). Normal results rule out
pheochromocytoma, although an elevation of more
than fourfold above the reference interval establishes
the diagnosis (77). False-positive results should be
considered in patients with equivocal elevation of plasma,
or urinary normetanephrine. In these subjects, measure-
ments should be repeated in the absence of possible
interfering conditions (77–79). A thorough discussion of
the diagnostic approach to pheochromocytoma is beyond
the scope of this Position Statement and the reader is
referred to recent comprehensive reviews (78, 79).
Screening of primary aldosteronism. According to the
Endocrine Society’s Clinical Guidelines for management
of primary aldosteronism and the AACE/AAES Medical
Guidelines for the management of adrenal incidentalo-
mas, all patients with an incidentally discovered adrenal
mass and hypertension should be tested for hyper-
aldosteronism (80, 81). The recent demonstration that
primary aldosteronism sustained by an adrenal ade-
noma may cause hypokalemia without hypertension
(82) supports the measurement of plasma aldosterone
and plasma renin activity (PRA), or direct renin
concentration, in all hypertensive or hypokalemic
patients. The evaluation should be performed paired at
mid morning in an outpatient after correction of
hypokalemia, if present; dietary salt intake must be
unrestricted (81, 83). Spironolactone must be discon-
tinued at least for 6 weeks. Angiotensin converting
enzyme inhibitors, angiotensin receptor blockers, dihy-
dropyridine calcium channel antagonists, b-blockers,
central a-2 antagonists (clonidine), non-steroidal anti-
inflammatory drugs, potassium-wasting diuretics,
amiloride, licorice, and chewing tobacco must be
discontinued at least for 4 weeks. Hypertension can be
controlled with non-interfering medication, such as
verapamil and/or doxazosin (80). The plasma aldoster-
one/renin ratio (ARR) should be calculated. Although
discrepant data of the literature preclude definition of a
certain threshold, primary aldosteronism should be
suspected in the presence of ARRO30–50 (plasma
aldosterone is expressed as ng/dl and PRA as ng/ml per
hour) (80, 84–87) or 3.7 (plasma aldosterone as ng/dl
and direct renin concentration as ng/l) (88, 89). A
thorough discussion of the diagnostic approach to
primary aldosteronism is beyond the scope of thisPosition Statement and the reader is referred to the
recent Endocrine Society’s Clinical Guidelines (80).
Screening of overt Cushing’s syndrome. According to the
Endocrine Society’s Clinical Guidelines for the diagnosis
of Cushing’s syndrome and the AACE/AAES Medical
Guidelines for the management of adrenal incidentalo-
mas, all patients with an incidentally discovered adrenal
mass should be tested for hypercortisolism (90). Excessive
overt cortisol should be suspected in the presence of one
out the following four symptoms that are relatively
specific for endogenous hypercortisolism: i) easy bruis-
ing, ii) facial plethora, iii) proximal myopathy or muscle
weakness, and iv) reddish-purple striae O1 cm wide
(89). As 24 h urinary free cortisol (UFC) is relatively
insensitive for the detection of mild hypercortisolism
(12), the 1 mg overnight dexamethasone suppression
test (1 mg DST) should be used for screening (5, 13, 16).
Setting the threshold at 1.8 mg/dl (50 nmol/l), 95%
sensitivity is achieved (91–93) but the physician should
be aware of conditions potentially leading to false-
positive, and less frequently to false-negative results
(94–96). A thorough discussion of the diagnostic
approach to overt Cushing’s syndrome is beyond the
scope of this Position Statement and the reader is referred
to the recent Endocrine Society’s Clinical Guidelines (90).
Evaluation of subclinical Cushing’s syndrome. We speci-
fically searched for articles including biochemical tests
to screen for subclinical Cushing’s syndrome (SCS) in
patients with adrenal incidentaloma. We decided to
select only studies with a caseload of at least 20 subjects
with incidentally discovered adrenal adenomas. We
have excluded the studies without either clearly defined
criteria to qualify for SCS or clear reporting of the
frequency of the abnormalities of the hypothalamic–
pituitary–adrenal (HPA) axis. However, only few studies
have reported the sensitivity and specificity of the
considered tests (DST, late-night serum or salivary
cortisol, urinary free cortisol, and ACTH) and inclusion
criteria were heterogeneous across the studies (Table 5).
SCS is the most frequent endocrine dysfunction
detected in patients with adrenal incidentalomas,
accounting from 5 to 20% of all cases. This variability
depends on the inclusion criteria, study design, work-up
protocols and mainly diagnostic criteria of SCS (13, 97).
A major challenge is that Cushing’s syndrome includes
a spectrum of clinical presentations that is difficult to
sort out in different categories. The heterogeneity of the
clinical phenotype mainly depends on the variability of
cortisol secretion that is distributed continuously from
apparently non-functioning adrenal adenomas to
overtly cortisol-producing adenomas. Categorization of
Cushing’s syndrome is also influenced by clinical
experience, because physicians who have less expertise
might overlook (mild) signs of hypercortisolism. For
these reasons, demonstration of SCS is extremely
difficult in practice. The standard biochemical tests
used to screen for overt Cushing’s syndrome arewww.eje-online.org
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have no sign of cortisol excess, or only non-specific
features, such as centripetal obesity, when patients
with ‘true’ adrenal incidentalomas are selected. In this
clinical setting, the a priori probability of SCS may be
roughly comparable with the false-positive rate of the
tests used for screening. Thus, it remains to be defined
what strategy is best suited to detect SCS, or silent
cortisol excess (97–99).
The DST has widely been employed to unmask subtle
abnormalities of cortisol secretion in patients with
adrenal incidentalomas and most authors use the
overnight 1 mg DST, which is easy to perform in clinical
practice (8, 12, 100–124). Sensitivity and specificity for
the 1 mg DST have been reported in four papers (8, 116,
117, 119), whereas only one of them has described the
diagnostic accuracy of UFC, ACTH, or late-night serum
cortisol (8). Available data suggest that the 1 mg DST
should be the first screening test; however, there is no
consensus on the test modality (single dose versus 2-day
administration). Moreover, a debate continues also
on the cutoff values to consider the test as positive.
To provide a standard, in 2002, the NIH state-of-the-
science conference panel recommended the 1 mg DST
with the traditional threshold of 5 mg/dl (138 nmol/l) to
define adequate suppression (5). Low cutoff values have
been advocated to increase detection of SCS following
the recommendations for screening of overt Cushing’s
syndrome (106, 108, 113, 114, 116, 117, 123).
However, specificity is an issue when post-dexametha-
sone cortisol thresholds as low as 1.8 mg/dl (50 nmol/l)
are used, which may result in more false-positive results
(116, 117). A recent addition to this controversy comes
from the French Society of Endocrinology who rec-
ommended a cutoff for the 1 mg DST at 1.8 mg/dl
(50 nmol/l) in the screening for SCS (125). Conversely,
according to the AACE/AAES Medical Guidelines for the
management of adrenal incidentalomas, diagnosis of
SCS is made if the serum cortisol level is O5.0 mg/dl
(138 nmol/l) after a 1 mg DST (81).
Other authors have suggested the standard 2-day
low-dose DST or high-dose (3 mg or even 8 mg) DST
(100, 101, 109–111, 113, 121–123). The 2-day low-
dose DST is more cumbersome to perform; therefore, it
may be considered as a confirmatory procedure or in the
context of psychiatric diseases, alcoholism and diabetes
mellitus, where it may have greater accuracy (90, 110).
Up to now, there is no direct head-to-head comparison
of the different DSTs, or different thresholds after the
1 mg DST, to establish a gold standard for diagnosing
SCS. However, in a recent study, the results of the
overnight 1 mg DST and 8 mg DST were compared in
22 out of 68 patients who did not suppress cortisol
below 1.8 mg/dl (50 nmol/l). The results of the 8 mg
DST did not change the probability to have SCS defined
by the 1 mg DST (126).
Markers of adrenal autonomy such as 24 h UFC
excretion, midnight serum cortisol, plasma ACTH, orrepeat DST after 3–6 months to confirm lack of
suppression are all plausible alternatives. However,
evaluation of UFC and ACTH is associated with
technical problems (90, 91), and the high-dose DSTs
have not been extensively employed for this problem.
Midnight serum cortisol may be used as a second-line
test, as it is cumbersome and expensive, even if it may
correlate better than other tests with clinical conditions
associated to hypercortisolism (124). Recent studies
have shown that normal late-night salivary cortisol
levels do not rule out SCS among patients with adrenal
incidentalomas. Thus, the late-night salivary cortisol
cannot be presently included in the screening
procedures for SCS until more data are available
(127–129).
A thorough assessment of the HPA axis in patients
with clinically inapparent adrenal adenomas may show
several combinations of abnormal tests pointing to
ACTH independence of cortisol secretion. Different
authors have used a number of criteria, often including
a pair of altered test results (8, 12, 103, 105, 111, 117,
119, 120). A second abnormal test result of HPA axis
function, such as a low or suppressed ACTH or a low
DHEAS concentration, supports the diagnosis according
to the AACE/AAES Guidelines (81). However, there are
conflicting data that do not allow to conclude that low
DHEAS concentration is a reliable, indirect marker of
autonomous cortisol secretion (103–106, 110, 130,
131). Moreover, DHEAS secretion physiologically
declines with age, and this may hamper recognition of
reduced DHEAS concentrations in aged population
(103, 130, 131).
In summary, the dilemma between a strategy aiming
to increase sensitivity and one oriented to favoring
specificity in the screening of SCS remains unsolved. As
the long-term consequences of the mild cortisol excess
that characterizes SCS have not been unequivocally
defined, a recent provocative paper casted doubts on the
value of extensive testing for this condition (15). In
principle, the panel accepts that there is insufficient data
linking patient’s outcome to the appointed diagnosis. In
other terms, the relationships between endocrine
findings and patient’s phenotype remain to be eluci-
dated (13). This complex issue is emphasized by the lack
of a simple correlation between the results of pre-
operative tests of the HPA axis and the postoperative
occurrence of corticotropic insufficiency that may be
considered as a demonstration of the previous existence
of some degree of cortisol excess (132). Thus, we are
recommending the use of stringent criteria to diagnose
this condition to reduce false-positive results that may
have negative psychological and economic conse-
quences, leading to further testing or even unnecessary
surgery.
The panel suggests a flexible approach guided by
clinical judgment. It seems biologically plausible to con-
sider that cortisol levels lower than 1.8 mg/dl (50 nmol/l)
after dexamethasone clearly exclude autonomouswww.eje-online.org
860 M Terzolo and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 164(ACTH-independent) cortisol secretion, whereas cortisol
levels higher than 5 mg/dl (138 nmol/l) likely indicate
SCS if no interfering conditions are present. Cortisol
values after dexamethasone between 1.8 (50 nmol/l) and
5 mg/dl (138 nmol/l) may be considered as indeterminate.
In such an event, it may be considered to extend
evaluation when features of Cushing’s syndrome are
present. The panel felt that these conclusions are sound
following a line of reasoning analogous to that of overt
Cushing’s syndrome but had to admit that there is
insufficient evidence to support this strategy.
Recommendations for hormonal assessment of
adrenal incidentalomas are given in Table 6.Natural history and management
Adrenal incidentaloma is not a uniform disease and its
natural history varies depending on the pathological
classification of the adrenal mass. It is obvious
that primary malignant adrenal tumors, and pheochro-
mocytomas, can significantly affect patients’ health.
However, the potential harm associated with clinically
inapparent adrenal adenomas, the most frequent
type among adrenal incidentalomas, is presently
unclear (13).
Although the frequency of tumors that can be
definitively dangerous for the patient is low among
patients with adrenal incidentalomas who are currently
referred to endocrinologists, it has to be considered that
both pheochromocytoma and ACC are potentially lethal
and patient’s outcome can be greatly improved by
timely adrenalectomy (78, 133). This justifies a low
threshold for recommending surgery in doubtful cases.
Patients bearing adrenal metastases have a clinical
course depending on stage, grade, and site of the
primary tumor (5). The other side of the problem is that
most of the non-functioning ACC, which account for
about 50% of all ACC, may be incidentally discovered
(9). ACC typically displays a rapid growth rate
(O2 cm/year) (16) and a poor outcome with a 5-year
survival of !50% (133). At present, we do not know
whether the prognosis of incidentally detected ACC is
different from functioning ACC. However, the only hope
of cure is the complete surgical removal of an early-
stage tumor (133).Table 6 Clinical recommendations on the hormonal assessment of a
1. We recommend ruling out pheochromocytoma in all patients with a
2. We recommend ruling out primary aldosteronism in all hypertensive a
3. We recommend ruling out overt Cushing’s syndrome in all patients
4. We recommend the 1 mg overnight DST for screening of subclinica
5. We suggest not to proceed with further testing in patients suppress
6. We suggest considering subclinical Cushing’s syndrome in patients
further testing in these patients. 24BBB
7. Present evidence is insufficient to recommend for or against consid
dexamethasone cortisol between 1.8 (50 nmol/l) and 5.0 mg/dl (138
Cushing’s syndrome, further testing may be indicated
For terminology of the strength of recommendations and graphical description
www.eje-online.orgPheochromocytoma can also lead to significant
morbidity and mortality if not diagnosed and treated
appropriately. An increasing number of pheochromo-
cytomas are clinically silent, and nearly 30% of all
pheochromocytomas show a nonspecific appearance at
the imaging studies. These tumors are most often
benign and the typical rate of growth is w0.5–
1.0 cm/year (16). Surgical resection is the treatment
of choice, but it does not guarantee cure because
recurrence can occur in as many as 17% of cases (134).
Thus, a careful follow-up, including biochemical testing
once a year, is advocated to ensure prompt diagnosis of
local recurrence or metastatic spread (135).
However, the large majority of adrenal incidentalo-
mas remain untreated, because the lesions display the
typical features of an adrenal adenoma without overt
signs and symptoms of hormonal hypersecretion. The
natural history and management of clinically inappar-
ent adrenal adenomas will be reviewed in the present
Position Statement.Questions
1. What is the risk of malignant transformation of
an adrenal incidentaloma? Available data on follow-
up of patients with adrenal incidentalomas suggest that
the large majority of adrenal lesions classified as benign
at diagnosis remain stable over time. In patients with
adrenal incidentalomas, followed up for an average of 4
years, 5–20% showed mass enlargementO1 cm and/or
appearance of another mass in the contralateral gland
(9, 17, 115, 119, 136). Mass enlargement was
generally limited to a 1–2 cm increase in diameter
over a period of 1–3 years (9). The presence of endocrine
abnormalities at diagnosis is not a reliable predictor of a
possible increase in tumor size during follow-up, as
previously thought (9, 119), because mass enlargement
was also described in patients with non-secreting
adrenal incidentalomas (13, 16). The threshold for
qualifying an increase in size as significant is unknown,
but it should be argued that most adrenal masses that
exhibit a pattern of slow growth are not malignant.
Moreover, occasional shrinkage, or even complete
disappearance, of an adrenal mass have also been
reported in about 4% of cases, most often when cysticdrenal incidentalomas.
drenal incidentalomas. 1444B
nd/or hypokalemic patients with adrenal incidentalomas. 144BB
with adrenal incidentalomas. 144BB
l Cushing’s syndrome. 14BBB
ing cortisol below 1.8 mg/dl (50 nmol/l) after DST. 24BBB
not suppressing cortisol below 5.0 mg/dl (138 nmol/l). We suggest
ering subclinical Cushing’s syndrome in patients with post-
nmol/l). In selected cases with clinical features suggestive of
of quality of evidence, see the legend of Table 1.
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diagnosed (9, 137).
In a recent review, Cawood et al. (15) found only two
reports of a malignancy detected during the follow-up of
adrenal incidentalomas thought to be benign at
diagnosis, a renal carcinoma metastasis (138) and a
non-Hodgkin’s lymphoma (119). Overall, the risk of an
untreated adrenal incidentaloma, qualified as a benign
lesion, subsequently developing malignancy appears to
be very low, !1 out of 1000 (9, 15, 115, 136). This
figure indirectly points out that the current imaging
strategy is adequate to ascertain the dignity of adrenal
incidentalomas.
2. What is the risk of evolution toward overt
hypersecretion? Abnormal adrenal function that is
not present at baseline may be detected during the
follow-up (16). The most common disorder reported
during follow-up is the occurrence of autonomous
cortisol secretion eventually leading to subclinical
cortisol excess. The onset of catecholamine overproduc-
tion or hyperaldosteronism during long-term follow-up
is very rare (9).
The studies that evaluated the risk of progression
from subclinical to overt Cushing’s syndrome are as a
whole reassuring and demonstrate that this event
occurs rarely, if ever. Development of overt Cushing’s
syndrome during the follow-up was observed in a
negligible number of cases,!1%, whereas appearance
of silent biochemical alterations was reported in a
percentage ranging from 0 to 11% across different
studies (9, 97). Masses of 3 cm or greater are more likely
to develop silent hyperfunction than smaller tumors,
and the risk seems to plateau after 3–4 years, even if it
does not subside completely (119, 139). Unilateral
uptake at baseline NP-59 scintigraphy has been
associated with persistence and progression of biological
SCS (98, 139). On the other hand, endocrine alterations
may spontaneously normalize during the follow-up (12,
137). This behavior raises the possibility of cyclical
cortisol secretion by clinically inapparent adrenal
adenomas (12).
3. What is the morbidity and mortality of SCS?
Notwithstanding the uncertainty regarding ascertain-
ment of SCS, there is no doubt that many patients may
be exposed to a chronic, albeit slight, cortisol excess
(140). Thus, it is biologically plausible to assume that
they should suffer from the classic complications of full-
blown Cushing’s syndrome, such as arterial hyperten-
sion, obesity, or diabetes. However, there is still scarce
information on the long-term detrimental effects, if any,
of silent hypercortisolism (97, 141–143).
An increased frequency of hypertension, central
obesity, impaired glucose tolerance or diabetes, hyperli-
pemia and osteoporosis has been described in patients
with SCS in a number of retrospective or cross-sectionalstudies (8, 97, 120–122, 124, 125, 142–148). The
results of these studies suggest that SCS may be
associated with the clinical phenotype of the insulin
resistance syndrome that fosters a number of unwanted
metabolic and vascular manifestations (142). However,
the interpretations of these data must be considered
with caution because there is the potential of confound-
ing and referral bias due to the limitations in the design
of the studies. An alternative hypothesis that adrenal
incidentaloma may itself be an unrecognized mani-
festation of the metabolic syndrome cannot be ruled out
(149), even if a causal link between SCS and insulin
resistance is the most plausible explanation for the
available data (140).
Despite the reported association between SCS and
the metabolic syndrome, which carries an enhanced all-
cause and cardiovascular mortality (150, 151),
evidence of increased mortality in patients who have
clinically inapparent adrenal adenomas and SCS is
lacking. The (scarce) available data suggest that most
patients with adrenal incidentalomas remain asympto-
matic throughout life (140–143). The cause of death
was mostly related to cardiovascular events, but it is
unknown whether the mortality rate is higher than the
general population (137, 140–143, 152). However, the
existing follow-up studies have almost exclusively
focused on the issues of potential malignant transfor-
mation and evolution of endocrine patterns. There are
few studies addressing outcome measures, but interpre-
tation of these follow-up studies is affected by their small
sample size and variable duration and modality of
follow-up. The potential for ascertainment bias should
be considered because many of these observations were
made in small, retrospective studies. The results of such
studies are outlined in the following chapter.
4. What is the management for SCS? A number of
underpowered studies reported improvement in either
hypertension or hyperglycemia in some patients with
SCS after adrenalectomy (120, 121, 131, 153, 154). In
a case–control study, Erbil et al. (155) compared the
outcome of adrenalectomy between 28 patients with
overt Cushing’s syndrome and 11 patients with SCS and
found quite unexpectedly that hypertension improved
more frequently among patients with the subclinical
syndrome. Tsuiki et al. (156) followed up 20 patients
with SCS for 15–69 months, ten of whom were
submitted to adrenalectomy, and the remaining patients
were managed conservatively. Of the total patients,
eight patients benefited from surgery in term of better
control of hypertension and/or hyperglycemia, whereas
half of the non-operated patients showed worsening of
their clinical conditions and the other remained
unchanged. Toniato et al. (157) carried out a prospec-
tive study in which 45 patients with SCS were randomly
selected for surgery (nZ23) or conservative manage-
ment (nZ22); mean duration of follow-up was about
8 years. They found that diabetes and hypertensionwww.eje-online.org
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surgical group; on the other hand, some worsening of
diabetes and hypertension was noted in conservatively
managed patients. The conclusion of the authors that
laparoscopic adrenalectomy appears more beneficial
than conservative management for patients with SCS
should be viewed with caution due to some methodo-
logical shortcomings of the study including the lack of a
formal comparison between the patients who were
operated and those who were not and the fact that
medical treatment of associated clinical conditions was
not standardized between groups. Sereg et al. (158)
carried out a retrospective uncontrolled study, in which
47 out of 125 patients with clinically non-functioning
adrenal adenomas underwent adrenalectomy, whereas
78 patients were followed up conservatively; these
patients were re-assessed after a mean follow-up time of
about 9 years (158). The frequency of cardiovascular or
cerebrovascular events did not significantly differ
between patients treated and not treated with adrena-
lectomy. At variance with the previous study, the
authors did not find any beneficial effect of surgery,
but it has to be pointed out that adrenalectomy was not
recommended for treatment of SCS, which was
diagnosed only in a minority of patients submitted to
surgery. Recently, Chiodini et al. (159) published a
retrospective controlled study on 108 patients followed
up for 18–48 months. Adrenalectomy was rec-
ommended to all patients with SCS and to all patients
without but with mass sizeO4 cm, or size increasing by
O1 cm during the follow-up. However, some patients
refused surgery, so four different groups were available
for comparison at baseline and at the last follow-up
(subclinical operated, subclinical not operated, non-
subclinical operated and non-subclinical not operated).
Adrenalectomy improved blood pressure and glucose
levels in patients with SCS compared with patients
treated conservatively. To a lesser extent, adrenalectomy
improved blood pressure also in patients without SCS
compared with patients treated conservatively (159).
This study suggests that surgery may be beneficial;
however, clinical improvement was not restricted to
patients with SCS casting some doubts on a cause and
effect relationship. Moreover, it has to be pointed out
that medical treatment was not standardized across the
different groups.
This inconsistent and incomplete evidence sum-
marized in Table 7, precludes any stringent recommen-
dation for the management of SCS. Limits of the
available literature on the outcome of surgical treat-
ment include heterogeneous definition of SCS, small
sample size, retrospective and uncontrolled nature of
most studies, variable duration of follow-up, and
inadequate definition of end-points and outcomes. In
particular, no study compared the outcome of adrena-
lectomy with that of best medical management of
associated diseases following specific treatment guide-
lines. Data from high-quality prospective trials arewww.eje-online.org
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indicate the superiority of a surgical or a non-surgical
approach (1, 13, 16, 97). Until the risks and benefits of
adrenalectomy are elucidated, it seems reasonable to
elect for surgery younger patients with SCS who display
diseases potentially attributable to excessive cortisol
(hypertension, diabetes, abdominal obesity, and osteo-
porosis) that are of recent onset, or are resistant
to optimal medical treatment, or are rapidly worsening
(1, 13, 16, 97, 141). The panel admits that this strategy
is based on pragmatism and not on robust evidence;
however, this commonsense advice has also been made
by Young (16). The AACE/AAES Medical Guidelines for
the management of adrenal incidentalomas reported
likewise that in patients with SCS, until further evidence
is available regarding the long-term benefits of adrena-
lectomy, surgical resection should be reserved for those
with worsening of hypertension, abnormal glucose
tolerance, dyslipidemia, or osteoporosis (recommen-
dation with a low level of evidence) (81). The NIH
state-of-the-science statement suggested that either
adrenalectomy or careful observation is a treatment
option for patients with subclinical autonomous
glucocorticoid hypersecretion. According to the NIH
panel, adrenalectomy has been demonstrated to correct
the biochemical abnormalities, but its effect on long-
term outcome and quality of life is unknown (5).
5. What is the surgical technique for adrenalect-
omy? Laparoscopic adrenalectomy is a safe and effective
procedure in skilled hands and it has become the
surgical technique of choice for benign masses (81,
160). The advantages of laparoscopic adrenalectomy
over traditional open adrenalectomy include a more
comfortable postoperative course, a shorter hospital
stay, rapid return to daily activities, and superior
cosmetic results. Controversy remains regarding the
safety and effectiveness of laparoscopic adrenalectomyTable 8 Clinical recommendation on the management of adrenal inci
1. We recommend surgery for any adrenal mass with radiological aspec
indicative of malignancy is unknown. 1444B
2. We recommend surgery in all patients with functional adrenal tumors
3. We recommend surgery in all patients with pheochromocytoma. 14
4. Data are insufficient to make any recommendation for or against su
5. We suggest postoperative glucocorticoid replacement in all patient
Replacement is mandatory in patients with subclinical Cushing’s sy
6. Data are insufficient to make firm recommendations on endocrine a
7. We suggest to repeat imaging (CT or MRI) 3–6 months after discov
mass, except when the adrenal mass is small (%2 cm) with clear b
features of myelolipoma or cyst, no additional follow-up is needed.
8. We suggest careful clinical monitoring of patients at high cardiovas
the specific guidelines (i.e. hypertension, diabetes). 244BB
9. We suggest considering adrenalectomy if the mass enlarges by 1 c
24BBB
10. We suggest considering adrenalectomy in patients with subclinica
reach the treatment goals of associated diseases potentially linke
11. We recommend laparoscopic adrenalectomy in all patients with p
For terminology of the strength of recommendations and graphical descriptionfor large lesions and lesions presumed to be malignant.
Several laparoscopic techniques have been developed
but no studies demonstrate a consistent benefit of one
laparoscopic approach (anterior or lateral transperito-
neal, posterior retroperitoneal) over another (5). The
rate of major complications from laparoscopic adrena-
lectomy is very low but not zero. The importance of
expertise and the existence of a learning curve should be
recognized (161, 162).
There is general consensus that patients with SCS
require postoperative glucocorticoid replacement to
prevent the risk of adrenal insufficiency (5, 81).
However, steroid coverage may also be required in
patients with nonfunctioning adenomas because no
hormonal parameter, or combination of parameters,
may predict the occurrence of post-surgical hypoadren-
alism (97, 132). The need of steroid replacement has to
be confirmed 1–2 months after surgery with appro-
priate testing. If post-surgical adrenal insufficiency is
confirmed, steroid replacement could be subsequently
tapered guided by clinical data and re-evaluation of the
HPA axis every 3–6 months. It is pertinent to say that
adrenal insufficiency may last for many months.
6. How to perform follow-up? How to follow-up
patients with adrenal incidentaloma is a controversial
issue. The NIH state-of-the-science statement suggested
repeating the hormonal screening, with an overnight
1 mg DST and measurement of urine catecholamines
and metabolites, annually for 4 years, as the risk of
hyperfunction seems to plateau after that period.
Further, it was considered reasonable in patients
whose lesions have not been excised to repeat CT
6–12 months after the initial study and to discontinue
radiological evaluation of lesions that do not increase in
size (5). In the AACE/AAES Medical Guidelines for the
management of adrenal incidentalomas, it is stated that
patients with adrenal incidentalomas who do not fulfill
the criteria for surgical resection need to havedentalomas.
ts compatible with malignancy. The threshold for a mass size clearly
causing overt steroid hormone or catecholamine excess. 14444
444
rgery in patients with subclinical Cushing’s syndrome.
s who undergo surgery for a presumed cortical adenoma.
ndrome and in patients without preoperative testing. 244BB
nd radiologic follow-up.
ery of an adrenal incidentaloma to recognize early a rapidly growing
enign features (density%10 HU). If an adrenal mass has clear
24BBB
cular risk and to treat adequately associated diseases according to
m or more and/or changes its appearance during observation.
l Cushing’s syndrome when an adequate medical therapy does not
d to hypercortisolism. 24BBB
resumably benign tumors who are submitted to surgery. 14444
of quality of evidence, see the legend of Table 1.
www.eje-online.org
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annually for 1–2 years. Hormonal evaluation should be
performed at the time of diagnosis and then annually for
5 years (81). In an influential review, Young (16)
recommended to repeat imaging at 6, 12, and 24
months, but an earlier evaluation may be worthwhile
when the mass is suspicious, although less frequent
imaging during follow-up is reasonable for patients with
small (!2 cm), uniform, hypodense cortical nodules,
provided they have no history of malignant disease.
Adrenalectomy is advised if the mass enlarges by 1 cm
or more, or if autonomous hormonal secretion develops
during follow-up. However, Young (16) correctly
recognized that the yield and cost-effectiveness of
repeated imaging at these intervals are uncertain. A
recent radiological review suggests that no follow-up is
needed when an adrenal mass has been qualified as a
myelolipoma or cyst and that the stability of an adrenal
mass for 1 year or more makes a benign diagnosis very
likely (73).
As a benign adrenal incidentaloma undergoes
malignant transformation rarely, if ever, and the risk
of developing clinically significant hormone hyperfunc-
tion during follow-up should not be a major concern, a
recent paper concluded that, based on the available
evidence, follow-up of adrenal incidentalomas initially
considered to be benign and not functional are likely to
result in significant costs, due to frequent false-positive
results, carries little clinical benefit and even confers a
non-negligible risk of fatal cancer due to CT-associated
radiation exposure (15). Thus, the authors recommend
against follow-up of all adrenal incidentalomas
with repeated imaging and hormone work-up as a
routine measure. It is our experience that repeating
imaging tests in masses with clear benign features
(size %2 cm and density %10 HU) is of limited utility.
The bottom line is that the limited and incomplete
evidence available precludes making any stringent
recommendation for periodic hormonal testing and
repeat imaging evaluation for follow-up purposes.
The panel agrees that the value of periodic hormonal
screening is uncertain but, if felt necessary, the 1 mg
DST may serve the purpose. In our opinion, however,
patients who are not candidates for surgery should be
followed up clinically to detect, treat, and control
cardiovascular risk factors that are usually overrepre-
sented in patients with adrenal incidentalomas, either
because they are exposed to excessive chronic cortisol or
because of a referral bias (such patients are more likely
to undergo imaging procedures). The simple and
important task of advising lifestyle changes and effective
medical treatment to reduce cardiovascular risk has to
be highlighted. Accordingly, Nieman (163) advocated
surgical treatment for patients with mild hypercortiso-
lism when medical treatment fails or there is pro-
gression of clinical features. Patients who develop
clinical signs of hormone excess, or experience worsen-
ing of their metabolic status and cardiovascular riskwww.eje-online.orgprofile despite optimal medical treatment, should be
re-tested for endocrine hyperfunction (164).
With regard to imaging, we recommend to repeat a
CT scan only once after 3–6 months, to be sure of not
missing a tumor whose malignant potential was missed
at diagnosis. Patients with small tumors,!2 cm, do not
need further imaging in most cases, but for larger
tumors, the decision to proceed or not with follow-up
imaging study should be judged on an individual basis,
taking into consideration the characteristics of the
mass, patient age, and history and results of endocrine
work-up (164). Patients with SCS who do not reach the
treatment goals of associated diseases potentially linked
to hypercortisolism (i.e. hypertension and diabetes),
despite an adequate medical therapy, or patients
with an adrenal incidentaloma showing a significant
(O1 cm) increase in size should be offered surgery. We
acknowledge that this clinically oriented strategy is
largely based on pragmatism but has the merit of
reducing costs and, possibly, increasing benefits
compared with current strategies. Moreover, it takes
into account the fact that many patients are worried if
no follow-up is offered.
Recommendations for the management of adrenal
incidentalomas are given in Table 8.Declaration of interest
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